Search results1 – 2 of 2
This paper aims to study the effects of a diet supplemented with flaxseeds on dyslipidemia, oxidative stress and proinflammatory cytokines, in rats consuming a…
This paper aims to study the effects of a diet supplemented with flaxseeds on dyslipidemia, oxidative stress and proinflammatory cytokines, in rats consuming a high-cholesterol diet.
Male Wistar rats (n = 30) weighing (250 ± 5 g) of which 10 were control and 20 were rendered hypercholesterolemic (HC) by feeding a diet enriched with 1% of cholesterol, for 15 days. After this phase, rats were divided into two groups; hypercholesterolemic group (HC) (n = 10), fed 20% casein diet enriched with 1% cholesterol; and hypercholesterolemic rats fed the same diet (n = 10), but additionally supplemented with flaxseeds (Linum usitatissimum) (Lu) powder, i.e. HC-Lu. Animals of the control group (n = 10) were fed the casein diet. All the animals were maintained on the respective diets for four weeks.
This study showed that in HC-Lu as compared to HC group, plasma total cholesterol, triacylglycerols and non-HDL cholesterol concentrations were respectively 2.4-, 1.5- and 3-fold lower. Also, the lipid peroxidation was reduced in red blood cells, organs (liver, heart and aorta) and lipoproteins (HDL2, HDL3 and VDL-LDL). A higher superoxide dismutase activity was observed in liver (+61%), heart (+62%) and aorta (+59%), whereas plasma proinflammatory cytokine (IL-1beta and IL-6) levels were decreased.
These results suggest that flaxseeds help to reduce hypercholesterolemia, oxidative stress and inflammation in patients with hypercholesterolemia.
This study aims to examine whether Globularia alypum (Ga) lyophilized aqueous leaves extract treatment improves cardiometabolic syndromes such as hyperglycemia, lipid…
This study aims to examine whether Globularia alypum (Ga) lyophilized aqueous leaves extract treatment improves cardiometabolic syndromes such as hyperglycemia, lipid profiles and oxidative damage resulting from a high-fructose diet induced in hypertriglyceridemic rats.
A total of 24 male Wistar rats weighing 80 ± 5 g were first randomly divided into 2 groups. A total of 12 control rats (C) were fed a standard-diet (St-D) and 12 high fructose (HF) rats were fed a high-fructose diet (HF-D) containing St-D in which cornstarch was substituted by fructose (61.4%). After 15 weeks of feeding, body weight (BW) was about 320 ± 20 g and hypertriglyceridemia was noted in HF vs C group (2.69 ± 0.49 mmol/L) vs (1.25 ± 0.33 mmol/L). Each group of rats was then divided into two equal groups (n = 6) and fed during four weeks either a St-D or HF-D, treated or not with 1% of Ga extract (C-Ga) and (HF-Ga). After 28 days, fasting rats were anesthetized and blood and tissues were removed to measure biochemical parameters.
The results showed no significant differences in BW and insulinemia between all groups. Ga extract supplementation reduced glycemia (−36%), glycosylated hemoglobin (−37%), Homeostasis Model of Assessment-Insulin Resistance index (−34%) and triacylglycerol’s contents in plasma (−33%), very low density lipoproteins–low density lipoproteins (VLDL-LDL) (−48%), liver (−52%) and aorta (−39%); total cholesterol concentrations in aorta was 3.7-fold lower in HF-Ga vs HF group. Ga treatment reduced lipid peroxidation in plasma, VLDL-LDL, red blood cells (RBC), liver, muscle and kidney by improving superoxide dismutase (SOD) activity and glutathione peroxidase (GPx) in RBC and catalase (CAT) activity in kidney (p < 0.05). Moreover, Ga ameliorates glutathione (GSH) production in RBC (+41%) and kidney tissues (+35%).
Ga extract ameliorated cardiometabolic syndrome by its hypotriglyceridemic effect and prevented development of insulin resistance. It reduces lipid peroxidation by enhancing non-enzymatic (GSH) and enzymatic (SOD, GPx and CAT) antioxidant defense systems in high-fructose hypertriglyceridemic rats. Therefore, supplementation of Ga leaves extract as an adjuvant could be used for the treatment of hypertriglyceridemia and the prevention and/or the management of cardio-metabolic adverse effects.